• Age ≥ 18 years

• Subject is admitted to the hospital with a primary diagnosis of Acute Decompensated Heart Failure (ADHF)

• Subjects receiving intravenous (IV) diuretic for decompensated heart failure and demonstrating fluid overload. This includes peripheral edema ≥2+ (on a 0 to 4+ scale) and a minimum of 1 of the following:

‣ Jugular venous distension ≥10 cm H20;

⁃ Pulmonary edema as determined by auscultation or imaging;

⁃ Hepatojugular reflux;

⁃ Paroxysmal nocturnal dyspnea or ≥ two-pillow orthopnea;

⁃ Dyspnea at rest with respiration rate ≥20 per minute.

• Total DAILY diuretic dose prior to admission of ≥80mg Lasix or equivalent

• Renal function parameters as measured by estimated glomerular filtration rate (eGFR) ≥20 ml/min/1.73m2

• Subject must meet on one of the following criteria:

‣ Subject has had a heart failure hospitalization or worsening of heart failure event requiring IV diuretic therapy (in hospital, emergency room, urgent care, or HF clinic) within the previous 6 months;

⁃ Renal function as measured by eGFR ≥20 and ≤45 ml/min/1.73m2;

⁃ At initial HF admission, \<600 ml of urine output within 6 hours of initial IV bolus or urine sodium of \<50 mmol/L at 1-2 hours after initial IV diuretic dose.

• Elevated N-Terminal (NT) Pro B-type Natriuretic Peptide (BNP) or BNP:

‣ NT Pro BNP \>1000 pg/ml (\>1500 for subjects with atrial fibrillation);

⁃ BNP \>250 pg/ml (\>375 for subjects with atrial fibrillation).

• Albumin \>2.5 g/dL

• Subject must be able to have device placement procedure within 96 hours of presentation to the hospital and still be demonstrating fluid overload at the time of device placement

⁃ Subject willing and able to complete study assessments and agrees to comply with all follow-up evaluations

⁃ Subject has provided written informed consent